Margaret qualified in 1985 and became a partner in 1991. She founded the firm's Financial Services and Markets Department, which she led for over twenty years, before becoming a consultant in 2015.
She advises on the law, practice and regulatory requirements relating to the financial services industry, and covers both contentious and non-contentious matters. Particular areas of interest include alternative asset management and trading, clearing and settlement systems. Her involvement with the alternative asset management industry includes representing it in engagement with regulators and Government, including for many years as a Council Member of the British Private Equity and Venture Capital Association and chair of its Regulatory Committee. Her experience of advising on infrastructure matters ranges from leading the Travers Smith team which advised the Bank of England on the legal framework for the CREST settlement system, where the daily settlement value of transactions in securities is now in excess of £1 trillion, to advising on the new requirements applicable to trading system operators under MiFID II.
She is the Deputy Chairman of and independent legal adviser to the Lloyds' Capacity Transfer Panel and the immediate past Chairman and a member of the City of London Law Society Regulatory Committee.
In 2010 she was inducted into the BVCA Hall of Fame, recognising her long term contribution to the industry and her success in her own field; The Lawyer magazine recognised Margaret in the 2011 edition of "The Hot 100"; in 2014 she received the Thomson Reuters award for Outstanding Long-Term Service to the Compliance Industry and in 2016 she was awarded the Distinguished Service Medal by the City of London Law Society for her work as chair of its Regulatory Committee. She is included in the Legal 500 Hall of Fame, which "highlights individuals who have received constant praise from their clients for their continued excellence".
Margaret combines her work with her role as trustee at two charities, Parkinson’s UK and Target Ovarian Cancer.